MELK inhibitor OTS167

Drug Overview

The medication known as OTS167 (also referred to as OTSSP167) is a potent, small-molecule inhibitor used in advanced cancer research. It is classified as a “Smart Drug” because it is designed to target a specific protein that is often overactive in aggressive tumors but nearly absent in most healthy adult tissues. By focusing on this specific biological “weak point,” OTS167 aims to stop cancer growth with high precision.

Here are the key details about this agent:

• Generic Name: MELK inhibitor OTS167 (OTSSP167).
• US Brand Names: None yet. It is currently an investigational drug used in clinical trials.
• Drug Class: Targeted Therapy / Maternal Embryonic Leucine Zipper Kinase (MELK) Inhibitor.
• Route of Administration: Intravenous (IV) infusion or Oral (capsule/tablet) in specific trial phases.
• FDA Approval Status: Investigational. It is not yet FDA-approved for general public use, but it is being studied in Phase 1 and Phase 2 clinical trials for various aggressive cancers.

What Is It and How Does It Work? (Mechanism of Action)

To understand OTS167, it helps to look at how certain “master controller” proteins drive cancer. OTS167 is a Targeted Therapy designed to sabotage a protein called MELK (Maternal Embryonic Leucine Zipper Kinase).

The Role of MELK

In a developing embryo, MELK helps cells grow and divide. In a healthy adult, this protein is usually “turned off.” However, in many types of cancer—especially those that are hard to treat—the MELK gene is reactivated. It acts like a stuck gas pedal, telling cancer cells to multiply uncontrollably and helping “cancer stem cells” survive even after chemotherapy.

Molecular Level Sabotage

OTS167 works by entering the cancer cell and binding to the MELK protein. Here is the process at the molecular level:

1. Competitive Inhibition: OTS167 fits into the “ATP-binding pocket” of the MELK enzyme. This prevents the enzyme from getting the energy it needs to function.
2. Disrupting Cell Division: MELK normally helps manage a process called mitosis (cell division). When OTS167 blocks MELK, the cancer cell’s “skeleton” (cytoskeleton) cannot organize correctly, leading to a “traffic jam” during division.
3. Inducing Apoptosis: Because the cell cannot divide properly and the survival signals are cut off, the cancer cell undergoes Apoptosis (programmed cell death).
4. Targeting Stem Cells: Uniquely, OTS167 is designed to kill cancer stem cells, which are the “seeds” of a tumor. By destroying these seeds, the drug aims to prevent the cancer from returning after treatment.

FDA Approved Clinical Indications

Because OTS167 is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being extensively studied in clinical trials for the following:

Oncological Uses (In Clinical Trials):

• Triple-Negative Breast Cancer (TNBC): Used for one of the most aggressive forms of breast cancer that lacks common receptors.
• Acute Myeloid Leukemia (AML): Investigated for blood cancers that have become resistant to standard chemotherapy.
• Lung Cancer: Specifically studied in Non-Small Cell Lung Cancer (NSCLC).
• Solid Tumors: Evaluated in patients with advanced cancers of the prostate, ovary, and pancreas.

Non-oncological Uses:

• There are currently no non-oncological uses for this drug.

Dosage and Administration Protocols

In clinical trial settings, the dosage of OTS167 is carefully adjusted based on the patient’s body surface area and their ability to tolerate the medicine.

Special Considerations

• Hepatic/Renal Insufficiency: Since the drug is processed by the liver, patients with significant hepatic impairment often require lower doses or are excluded from early trials for safety.

Clinical Efficacy and Research Results

Recent clinical studies (between 2020 and 2025) have highlighted both the potential and the challenges of MELK inhibition.

• Tumor Shrinkage: In early Phase 1 trials, a subset of patients with Triple-Negative Breast Cancer and AML showed “Stable Disease” or “Partial Response,” meaning their tumors stopped growing or shrank significantly.
• Biological Activity: Research confirmed that OTS167 successfully reduced MELK activity in patients’ blood and tumor samples, proving the “Smart Drug” was hitting its intended target.
• Overcoming Resistance: Numerical data from laboratory models combined with human data suggests that OTS167 can make standard chemotherapy more effective by “sensitizing” the cancer cells, potentially increasing the success rate of combined treatments by approximately 20 to 30 percent in resistant models.

Safety Profile and Side Effects

As a targeted therapy, OTS167 is designed to be more selective than chemotherapy, but it still has a distinct side effect profile because MELK can play roles in certain healthy processes like blood cell production.

Common Side Effects (>10%):

• Gastrointestinal Issues: Nausea, vomiting, and diarrhea are common, though usually manageable.
• Fatigue: A general sense of tiredness or lack of energy.
• Decreased Appetite: Temporary loss of interest in food.

Serious Adverse Events:

• Neutropenia: A significant drop in white blood cells, which can increase the risk of serious infections.
• Thrombocytopenia: A drop in blood platelets, which may lead to easier bruising or bleeding.
• Liver Enzyme Elevation: Temporary stress on the liver that requires close monitoring.

Black Box Warning: There is no FDA Black Box Warning for this investigational agent.

Management Strategies:

• Blood Count Monitoring: Patients must have their blood checked weekly to ensure white blood cell levels remain safe.
• Anti-emetics: Doctors often provide anti-nausea medication before the dose is given.
• Hydration: Patients are encouraged to drink plenty of fluids to protect their kidneys and manage digestive side effects.

Connection to Stem Cell and Regenerative Medicine

OTS167 is at the forefront of Cancer Stem Cell research. Standard treatments often kill the “bulk” of a tumor but leave behind a small population of stem cells that can rebuild the cancer later. Because MELK is a critical survival factor for these stem cells, OTS167 is considered a pioneer in “Stem Cell-Directed Therapy.” Scientists are researching how this drug can be used to “cleanse” the body of these seeds, potentially allowing the body’s natural Regenerative Medicine processes to repair healthy tissue without the threat of cancer recurrence.

Patient Management and Practical Recommendations

To ensure safety and the best possible results during a clinical trial, patients should follow these guidelines.

Pre-treatment Tests to be Performed:

• MELK Expression Test: Doctors may biopsy the tumor to see if it has high levels of the MELK protein.
• Complete Blood Count (CBC): To ensure baseline blood levels are healthy.
• Liver Function Test (LFT): To check the health of the liver before starting.

Precautions During Treatment:

• Infection Control: Because your white blood cells may drop, avoid large crowds and people who are visibly sick.
• Sun Protection: Some targeted therapies can make the skin more sensitive to sunlight.

“Do’s and Don’ts” List:

• DO report any fever over 100.4°F (38.0°C) to your medical team immediately.
• DO keep a diary of any digestive changes to help your doctor manage side effects.
• DON’T take any new over-the-counter herbal supplements without asking your oncology team first.
• DON’T skip scheduled blood tests, as these are the “early warning system” for your safety.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. OTS167 is an investigational drug and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.